Gene Expression Profiling for Graft Tolerance Phenotype Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for transplant patients are associated with undesirable side effects and long-term risks, necessitating the identification of individuals who are tolerant to their grafts to reduce or discontinue therapy without risking graft rejection.
Innovation Solution
Methods for determining a graft tolerant phenotype by evaluating gene expression in samples, such as blood, using gene expression profiles to identify individuals who can manage immunosuppressive therapy effectively, including reducing or discontinuing it safely.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive therapy is administered to maintain graft viability, then graft rejection is prevented, but undesirable side effects and long-term risks increase
Solution Approach 1:
The patent changes the parameter of immunosuppressive therapy from continuous fixed-dose administration to dynamic adjusted-dose administration based on gene expression monitoring. By monitoring expression levels of tolerance-associated genes (such as FOXP3, IL-10, TGF-beta) and rejection-associated genes, the therapy intensity is adjusted to maintain graft viability while minimizing harmful effects.
Solution Approach 2:
The patent implements a feedback mechanism where gene expression profiles are continuously monitored and used to adjust immunosuppressive therapy. The expression levels of specific genes serve as feedback signals indicating the subject's tolerance status, allowing real-time optimization of therapy to balance graft protection with reduction of side effects.
2Object-affected harmful factors
If immunosuppressive therapy is discontinued to reduce side effects, then harmful factors decrease, but graft rejection risk increases
Solution Approach 1:
The patent performs preliminary assessment of tolerance status through gene expression analysis before making decisions about therapy discontinuation. By evaluating expression profiles of tolerance-associated genes in advance, the system identifies subjects who have developed natural tolerance and can safely reduce or discontinue immunosuppressive therapy, preventing both unnecessary side effects and premature rejection.
Solution Approach 2:
The patent transitions from binary therapy decisions (continue/discontinue) to graduated therapy adjustment based on gene expression parameters. Therapy intensity is modulated according to quantitative gene expression levels, allowing incremental reduction of immunosuppression in tolerant subjects while maintaining protection in non-tolerant subjects.
3Adaptability or versatility
If gene expression profiling is performed to identify tolerant individuals, then personalized therapy management is enabled, but measurement and detection complexity increases
Solution Approach 1:
The patent segments the complex gene expression analysis into manageable components: (1) selection of specific tolerance-associated genes for monitoring, (2) standardized assay protocols for each gene, and (3) interpretation algorithms for clinical decision-making. This segmentation makes the overall process more tractable and implementable in clinical settings.
Solution Approach 2:
The patent introduces standardized gene expression profiles as intermediaries between complex molecular biology and clinical decision-making. These predefined profiles serve as mediators that translate complex gene expression data into actionable clinical information, simplifying the interpretation process for clinicians.
Data Source
AI summary
Methods are provided for determining whether a subject has a graft tolerant phenotype. In practicing the subject methods, the expression of at least one gene in a sample from the subject, e.g., a blood sample, is assayed to obtain an expression evaluation for the at least one gene. The obtained expression evaluation is then employed to determine whether the subject has a graft tolerant phenotype. Also provides are compositions, systems and kits that find use in practicing the subject methods. The methods and compositions find use in a variety of applications, including the determination of an immunosuppressive therapy regimen.